| 摘要 |
<p>The present invention relates to novel glycoforms and preparations of the soluble complement receptor type 1 (sCR1), and their uses in the therapy of complement mediated diseases and disorders involving inflammation and inappropriate complement activation and in thrombotic or shock state conditions. The invention provides novel glycoforms and methods for producing, detecting, enriching and purifying such glycoforms. The invention further provides methods of specifically producing a glycoform by recombinant or chemical means. Preferred embodiments of the invention include sialylated glycoforms and glycoforms with a pI « 5.1 determined by chromatofocusing or with a sialic acid to mannose molar ratio of » 0.25. The glycoforms may be formulated alone in therapeutic compositions or in combination with thrombolytic agents.</p> |
